United States Securities and Exchange Commission · EDGAR Accession 0001872856-26-000133

Form C-AR

Annual Report — Regulation Crowdfunding
Issuer CIK 2042609
Period 2025-12-31

Eliaz Therapeutics Inc.

CorporationDEIncorporated 2015SANTA ROSA, CAeliaztherapeutics.com
B

Financial Condition

two fiscal years, as filed
Revenue +10% YoYBurn increasingDebt / assets 380%2 employees
Line itemMost recent FYPrior FYΔ
Revenue332,235302,481▲ 10%
Cost of goods sold00
Net income(1,745,041)(954,869)▼ burn
Total assets2,589,276738,015▲ 251%
Cash & equivalents1,799,51032,814
Accounts receivable00
Short-term debt1,796,7312,346,085▼ 23%
Long-term debt8,033,1173,888,186▲ 107%
Taxes paid00

Figures in USD as reported by the issuer.